EGFR and neoplasm: Although the LU0858 PDX models had EGFR L858R mutation, erlotinib as a single-agent treatment at 30 mg/kg did not exhibit any anti-tumor activity, with no statistically significant difference compared with the vehicle control (P > 0.05).